Tyrosine kinase inhibitor SU6668 represses chondrosarcoma growth via antiangiogenesis in vivo

BACKGROUND: As chondrosarcomas are resistant to chemotherapy and ionizing radiation, therapeutic options are limited. Radical surgery often cannot be performed. Therefore, additional therapies such as antiangiogenesis represent a promising strategy for overcoming limitations in chondrosarcoma therap...

Descripción completa

Detalles Bibliográficos
Autores principales: Klenke, Frank M, Abdollahi, Amir, Bertl, Elisabeth, Gebhard, Martha-Maria, Ewerbeck, Volker, Huber, Peter E, Sckell, Axel
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1832206/
https://www.ncbi.nlm.nih.gov/pubmed/17367541
http://dx.doi.org/10.1186/1471-2407-7-49

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1832206/
https://www.ncbi.nlm.nih.gov/pubmed/17367541
http://dx.doi.org/10.1186/1471-2407-7-49

Ejemplares similares